Health News
Date: Jun-14-2012
Individuals with type 2 diabetes could significantly benefit from a protein-rich meal replacement called Almased®, according to results of a pilot study. The researchers enrolled 22 obese adults with type 2 diabetes in the 12 week pilot study. For the first week, participants replaced all three daily meals with Almased. For the second to forth week, they ate a protein-rich lunch in addition to two meals with Almased, and for the rest of the study duration they only replaced one meal...
Date: Jun-14-2012
US scientists have found a way to grow new bone using fresh, purified stem cells from fat tissue that produces better quality bone faster than conventional methods. They suggest this may one day eliminate the need for painful bone grafts that use material taken from patients with invasive surgery. They write about their work in the 11 June online first issue of a paper published in the new peer-reviewed journal Stem Cells Translational Medicine, which aims to span stem cell research and clinical trials...
Date: Jun-14-2012
Scientists working on a huge project that has mapped all the different microbes that live in and on a healthy human body have made a number of remarkable discoveries, including the fact that harmful bacteria can live in healthy bodies and co-exist with their host and other microbes without causing disease. This week sees the publication of several papers from the Human Microbiome Project (HMP), including two in Nature and two in PLoS ONE...
Date: Jun-14-2012
Experts at Southampton's teaching hospitals have pioneered the use of a revolutionary device to help people overcome embarrassing bladder problems at the click of a button - without drugs, needles or surgery. The VERV system, which involves a small patch placed on the lower back and a remote control, is the first device to halt the symptoms of overactive bladder (OAB) syndrome from outside the body via wireless technology...
Date: Jun-14-2012
A principal standing in the hallway says, "You are one of my favorite students!" In class, a smart girl says, "You are the nicest person in our class!" Many children would smile and eagerly return those compliments, but some with social anxiety may be too terrified to respond. Researchers at the University of Central Florida's Anxiety Disorders Clinic and the Atlanta-based company Virtually Better want to give more children with social anxiety the practice they need to become comfortable in social situations...
Date: Jun-14-2012
Cachexia, a syndrome characterized by rapid weight loss and muscle deterioration, is a major cause of death among patients suffering from diseases like cancer, AIDS and chronic infection. In fact, 30 per cent of cancer-related deaths are the result of cachexia-induced muscle loss rather than the primary malignancy. And while scientists are making strides in gaining a better understanding of this deadly condition, no effective anti-cachectic therapies exist to date...
Date: Jun-14-2012
A mutant form of a meek microbe deals a gutsy blow to colon cancer, University of Florida scientists have discovered. The special bacteria halted abnormal inflammation, reduced precancerous growths and reversed progression of severe cancerous lesions in the large intestines of mice. The findings appear June 11 in the Proceedings of the National Academy of Sciences. "We have demonstrated that our bacterial treatment can take on established colon cancer," said principal investigator Mansour Mohamadzadeh, Ph.D...
Date: Jun-14-2012
iWalk, the personal bionics company advancing technology to restore natural movement for lower-limb amputees, today announced the availability of its BiOM bionic lower limb system for above-knee amputees (BiOM AK). The new BiOM AK is an ankle system that works with select microprocessor knees to restore natural motion through personalized bionic technology. Personal bionic devices are fundamentally redefining the standard of care for those with limb loss by not merely emulating human function, but enhancing it...
Date: Jun-14-2012
Novartis is presenting data at the American Diabetes Association's (ADA) 72nd Scientific Sessions in Philadelphia, USA that demonstrate the safety and efficacy profile of Galvus® (vildagliptin) in combination with insulin in patients with type 2 diabetes11. Novartis is also announcing the launch of VERIFY, a five-year study that is intended to examine if vildagliptin has the potential to slow the progressive decline in blood sugar control in patients with type 2 diabetes when used in combination with metformin within two years of diagnosis2...
Date: Jun-14-2012
Two papers published in the European Journal of Preventive Cardiology (1,2) complete the publication of data from the pitavastatin development programme by Japanese-headquartered company, Kowa. Kowa now has clinical study data from nearly 25,000 patients for its novel and potent statin, pitavastatin, showing its efficacy and pharmacokinetics are consistent across the world. The last tranche of primary data show pitavastatin is as effective as other commonly used statins at lowering low density lipoprotein cholesterol (LDL-C), with excellent tolerability...